ECEESPE2025 Poster Presentations Thyroid (141 abstracts)
miRNA expression profiles in braf v600e positive thyroid tumors
Karolina Mastnikova 1 , Vlasta Kuklikova 1 , Barbora Bulanova 1 , Olivia Cillikova 1 , Katerina Vyhnalova 1 , Marie Rodova 1 , Eliska Vaclavikova 1 , Jitka Carkova 1 , Rami Katra 2 , Petr Vlcek 3 , Daniela Kodetova 4 , Martin Chovanec 5 , Jana Drozenova 6 , Radoslav Matej 6 , Jaromir Astl 7 , Jiri Hlozek 8 , Jiri Soukup 7 , Josef Vcelak 1 & Bela Bendlova 1
1Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic; 22nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Department of Ear, Nose, and Throat, Prague, Czech Republic; 32nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Department of Nuclear Medicine and Endocrinology, Prague, Czech Republic; 42nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Department of Pathology and Molecular Medicine, Prague, Czech Republic; 5Department of Otorhinolaryngology, 3rd Faculty of Medicine, Charles University in Prague and University Hospital Kralovske Vinohrady, Prague, Czech Republic; 63rd Faculty of Medicine, Charles University in Prague and University Hospital Kralovske Vinohrady, Department of Pathology, Prague, Czech Republic; 73rd Faculty of Medicine and Military University Hospital, Departments of Pathology, Prague, Czech Republic; 8Departments of 7Otorhinolaryngology and Maxillofacial Surgery, and 8Pathology, 3rd Faculty of Medicine and Military University Hospital, Prague, Czech Republic
JOINT3550
Objective: Thyroid tumours are more often diagnosed and prognosticated using molecular testing. Accounting for approximately 85-88% of cases, papillary thyroid carcinoma (PTC) is the most common subtype of thyroid cancer. The BRAF p.(Val600Glu) variant is the most prevalent genetic alteration in PTC or papillary thyroid microcarcinoma (PTmC) and is associated with aggressive clinicopathological features and an increased risk of disease-related mortality. However, many of these aggressive features can only be identified postoperatively on histological specimens. The miRNA expression profile is an additional tool that is being explored in the diagnosis of thyroid cancer to help fill this gap in our knowledge.
Methods: In this study, we examined the expression profiles of miRNAs in PTC samples harbouring the BRAF p.(Val600Glu) variant, focusing on comparing the group of BRAF-positive PTC cases with indolent tumour behaviour (patients with T1/T2N0M0 without angioinvasion, persistence or recurrence) with more aggressive PTC cases (e.g. patients with lymphatic or distant metastases, angioinvasion, extrathyroidal invasion or radioiodine-refractory PTC). The QIAseq miRNA Library Kit (Qiagen) was used to generate miRNA libraries from fresh frozen thyroid tissue samples and for the bioinformatic comparison of the expression profiles, the miRge3.0 tool and the DESeq2 package in R were used.
Results: In BRAF-positive samples, a total of 80 miRNAs showed significantly altered expression (44 upregulated, 36 downregulated) compared to healthy thyroid tissue. The expression of 10 miRNAs exhibited significantly altered expression in more aggressive PTC cases - 7 miRNAs were significantly upregulated and 3 miRNAs were significantly downregulated. The most significant findings were upregulated expression of hsa-miR-642a-5p, hsa-miR-205-5p, hsa-miR-150-5p and downregulated expression of hsa-miR-520a-5p, hsa-miR-181d-5p and hsa-miR-3065-5p.
Conclusion: In conclusion, knowledge of the expression of miRNAs could be a useful tool for better prognosis. Our data suggest that the indolent and aggressive behaviour of PTC cases can be differentiated using miRNA expression profiles. Verification using a different method and the analysis of a larger set of samples are to follow. Supported by AZV NU21-01-00448 and MH CZ RVO 00023761.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more